This study is currently recruiting patients with alveolar soft-part sarcoma only, and is no longer recruiting patients with synovial sarcoma or leiomyosarcoma.
Full title: A Phase III Study of AL3818 (Anlotinib, Catequentinib) Hydrochloride Monotherapy in Subjects With Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma
This study assesses the safety and effectiveness of AL3818 (anlotinib) hydrochloride in the treatment of metastatic or advanced alveolar soft part sarcoma, leiomyosarcoma, and synovial sarcoma.
More information can be found at clinicaltrials.gov
To find out more about this trial and whether you could take part, talk to your clinical team.